Sino Biopharmaceutical Forms Indonesia Joint Venture With Tempo Scan
Nomura Expects AKESO to Swing to Interim Profit of RMB46M, Maintains Buy Rating
Nomura Raises WUXI BIO TP to HKD51.38, Estimates 1H Profit to Drop 15%
BeOne Medicines Ltd (6160) Gets a Buy from Nomura
WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
WuXi Biologics added to FTSE4Good Index Series for sixth straight year